Role of immunotherapy in the treatment of advanced non-small-cell lung cancer

Future Oncology

Volumn 10, Issue 1, 2014, Pages 79-90

  Rijavec, Erika ^a   Genova, Carlo ^a   Alama, Angela ^a   Barletta, Giulia ^a   Sini, Claudio ^a   Pronzato, Paolo ^a   Coco, Simona ^a   Bello, Maria Giovanna Dal ^a   Savarino, Graziana ^a   Truini, Anna ^a   Boccardo, Francesco ^a,b   Grossi, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

advanced non small cell lung cancer; cancer vaccine; CTLA 4; IL 2; immunotherapy; PD 1; TLF; TLR9

Indexed keywords

AGATOLIMOD; BELAGENPUMATUCEL L; BMS 936559; CANCER VACCINE; EPIDERMAL GROWTH FACTOR; IPILIMUMAB; LACTOFERRIN; MONTANIDE ISA 51; MUCIN 1; NIVOLUMAB; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; TECEMOTIDE; TG 4010; TLF PROTEIN; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MDX-1106; MONOCLONAL ANTIBODY; OLIGODEOXYRIBONUCLEOTIDE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TLR9 PROTEIN, HUMAN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); HUMAN; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; CYTOKINES; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; OLIGODEOXYRIBONUCLEOTIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; TOLL-LIKE RECEPTOR 9;

EID: 84902130427     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.145     Document Type: Review

References (68)

1. Jemal E, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J. Clin. 54(1), 8-29 (2004).
2. Karim-Kos H, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh J. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur. J. Cancer 44(10), 1345-1389 (2008).
3. Woo EY, Yeh H, Chu CH et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272-4276 (2002).
4. Disis ML. Immune regulation of cancer. J. Clin. Oncol. 28(29), 4531-4538 (2010).
5. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6(11), 836-848 (2006).
6. Marincola FM, Jaffee EM, Hicklin DJ et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
7. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 480(7378), 480-489 (2011).
8. Declerck S, Vansteenkiste J. Immunotherapy for lung cancer: ongoing clinical trials. Future Oncol. doi:10.2217/FON13.145 (2013) (Epub ahead of print).
9. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249-293 (2004).
10. Butts C, Maksymiuk A, Goss G et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol. 137(9), 1337-1342 (2011).
11. Quoix E, Ramlau R, Westeel V et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled Phase 2B trial. Lancet Oncol. 12(12), 1125-1133 (2011).
12. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced NSCLC. J. Clin. Oncol. 26(9), 1452-1458 (2008).
13. Tzai TS, Shiau AL, Liu LL, Wu CL. Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of BMT-2 tumor-bearing mice through upregulation of MCH class I and Fas expressions. Anticancer Res. 20(3A), 1557-1562 (2000).
14. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4721-4730 (2006).
15. Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 18(1), 47-51 (1995).
16. Tester WJ, Kim KM, Krigel RL et al. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer 25(3), 199-206 (1999).
17. Jansen RL, Slingerland R, Goey SH et al. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J. Immunother. 12(1), 70-73 (1992).
18. Lissoni P, Tisi E, Barni S et al. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br. J. Cancer 66(1), 155-158 (1992).
19. Lissoni P, Barni S, Tancini G et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer 69(1), 196-199 (1994).
20. Correale P, Tindara Miano S, Remondo C et al. Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biol. Ther. 8(6), 497-502 (2009).
21. Ridolfi L, Bertetto O, Santo A et al. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a Phase III randomized multicentric trial. Int. J. Oncol. 39(4), 1011-1017 (2011).
22. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J. Immunol. 162(10), 5813-5824 (1999).
23. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18(2), 2006-2013 (2006).
24. Contardi E, Palmisano GL, Tazzari PL et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interection. Int. J. Cancer 117(4), 538-550 (2005).
25. Salvi S, Fontana V, Boccardo S et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 61(9), 1463-1472 (2012).
26. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26(32), 5275-5283 (2008).
27. Keir ME, Butte MJ, Freeman GJ et al. PD-1 and its ligand in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
28. Lee SJ, Jang BC, Lee SW et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett. 580(3), 755-762 (2006).
29. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2(3), 261-268 (2001).
30. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
31. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10(15), 5094-5100 (2004).
32. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56(8), 1173-1182 (2007).
33. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin. Genitourin. Cancer 5(3), 206-211 (2006).
34. Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360-3365 (2007).
35. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
36. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
37. Genova C, Rijavec E, Barletta G et al. Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin. Biol. Ther. 12(7), 939-948 (2012).
38. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30(17), 2046-2054 (2012).
39. Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase 2 trial. Ann. Oncol. 24(1), 75-83 (2013).
40. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
41. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
42. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologics 80(3), 252-267 (1995).
43. de la Rosa G, Yang D, Tewary P et al. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J. Immunol. 180(10), 6868-6876 (2008).
44. Parikh PM, Vaid A, Advani SH et al. Randomized, double-blind, placebo-controlled Phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small cell lung cancer that progressed after chemotherapy. J. Clin. Oncol. 29(31), 4129-4136 (2011).
45. Wang Y, Raghunadharao D, Raman G et al. Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial. J. Clin. Oncol. 24(Suppl.), Abstract 7095 (2006).
46. Ramalingam SS, Crawford J, Chang A et al. FORTIS-M, a randomized, double-blind, placebo-controlled Phase 3 study of oral talactoferrin alfa with best supportive care in patients with advanced non-small cell lung cancer following two or more prior regimens-by The FORTIS-M Study Group. Ann. Oncol. 23(9), Abstract 2347 (2012).
47. Krieg AM. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117(5), 1184-1194 (2007).
48. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27(2), 161-167 (2008).
49. Manegold C, Gravenor D, Woytowitz D et al. Randomized Phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(24), 3979-3986 (2008).
50. Hirsh V, Paz-Ares L, Boyer M et al. Randomized Phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 29(11), 667-674 (2011).
51. Manegold C. Randomized Phase III trial of gemcitabine/cisplatin with or without PF3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26(Suppl.), Abstract 801 (2008).
52. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
53. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
54. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59-73 (2008).
55. Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc. Am. Thorac. Soc. 6(2), 224-232 (2009).
56. Salem ML, Kadima AN, El-Naggar SA et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 30(1), 40-53 (2007).
57. Reits E, Hodge J, Herberts C et al. Radiation modulates the peptide repertoire, enhance MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203(5), 1259-1271 (2006).
58. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174(12), 7516-7523 (2005).
59. Quarmby S, Hunter RD, Kumar S. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res. 20(5B), 3375-3381 (2000).
60. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol. Immunother. 60(3), 433-442 (2011).
61. Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ. Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J. Immunother. 31, 586-590 (2008).
62. NCT01383148. Phase IIB/IIIB of TG4010 immunotherapy in patients with stage IV non-small cell lung cancer (TIME). http://clinicaltrials.gov/ct2/show/NCT01383148?term=tg4010&rank=1
63. NCT01444118. A randomized trial to study the safety and efficacy of EGF cancer vaccination in late stage (IIIB/IV) non-small cell lung cancer patients (NSCLC). http://clinicaltrials.gov/ct2/show/NCT01444118?term=egfvaccineandnsclc &rank=1
64. NCT00676507. Phase III Lucanix™ vaccine therapy in advanced non-small cell lung cancer (NSCLC) following front-line chemotherapy (STOP). http://clinicaltrials.gov/ct2/show/NCT00676507?term=BELAGENPUMATUCELandnsclc&rank=1
65. Safety and efficacy trial of ipilimumab versus pemetrexed in non-squamous non-small cell lung cancer. http://clinicaltrials.gov/ct2/show/NCT01471197?term=ipilimumabANDNS CLC&rank=3
66. Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. http://clinicaltrials.gov/ct2/show/NCT01285609?term=ipilimumabANDNSCLC&rank=2
67. Safety and efficacy of talactoferrin in addition to standard chemotherapy in patients with non-small cell lung cancer (FORTIS-C). www.clinicaltrials.gov/ct2/show/NCT00706862?term=fortis-c&rank=1
68. Ipilimumab US prescribing information: risk evaluation and mitigation strategy (REMS). www.yervoy.com/hcp/rems.aspx